Analysts Set Nkarta, Inc. (NASDAQ:NKTX) PT at $13.25

Nkarta, Inc. (NASDAQ:NKTX) has earned an average rating of “Moderate Buy” from the six analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $13.25.

NKTX has been the topic of several recent analyst reports. Stifel Nicolaus dropped their target price on shares of Nkarta from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, November 11th. Wall Street Zen upgraded shares of Nkarta from a “sell” rating to a “hold” rating in a research note on Saturday, November 29th. Needham & Company LLC restated a “buy” rating and issued a $10.00 target price on shares of Nkarta in a report on Wednesday, August 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nkarta in a research report on Friday, October 31st.

Hedge Funds Weigh In On Nkarta

A number of hedge funds have recently modified their holdings of the company. Jane Street Group LLC grew its stake in shares of Nkarta by 118.7% in the first quarter. Jane Street Group LLC now owns 134,286 shares of the company’s stock worth $247,000 after acquiring an additional 852,559 shares during the last quarter. Monaco Asset Management SAM lifted its stake in shares of Nkarta by 94.7% in the second quarter. Monaco Asset Management SAM now owns 1,583,372 shares of the company’s stock worth $2,628,000 after buying an additional 770,256 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Nkarta during the third quarter valued at approximately $1,549,000. Alyeska Investment Group L.P. increased its position in shares of Nkarta by 54.7% during the first quarter. Alyeska Investment Group L.P. now owns 2,064,956 shares of the company’s stock valued at $3,800,000 after acquiring an additional 730,260 shares in the last quarter. Finally, AWM Investment Company Inc. increased its position in shares of Nkarta by 150.0% during the first quarter. AWM Investment Company Inc. now owns 1,000,000 shares of the company’s stock valued at $1,840,000 after acquiring an additional 600,000 shares in the last quarter. Hedge funds and other institutional investors own 80.54% of the company’s stock.

Nkarta Price Performance

NKTX opened at $1.84 on Tuesday. Nkarta has a fifty-two week low of $1.31 and a fifty-two week high of $2.79. The company’s 50 day moving average price is $2.06 and its two-hundred day moving average price is $2.00. The firm has a market capitalization of $130.70 million, a price-to-earnings ratio of -1.33 and a beta of 0.80.

Nkarta (NASDAQ:NKTX) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.03. As a group, equities research analysts predict that Nkarta will post -1.7 EPS for the current year.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.